Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth W Mahaffey

Showing results (471-480 of 636) with videos related to

Pageof 64
Sort By:
The New England Journal of Medicine|November 6, 2012
Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis, Glenn M Chertow, Geoffrey A Block, et al.
Nature Medicine|June 24, 2024
Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trialJohannes F E Mann, Peter Rossing, George Bakris, et al.
International Journal of Cardiology|May 2, 2009
Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: results from SYNERGYSarah A Spinler, Kenneth W Mahaffey, Dianne Gallup, et al.
JAMA Cardiology|July 4, 2019
Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial FibrillationSean D Pokorney, DaJuanicia N Holmes, Laine Thomas, et al.
Journal of the American College of Cardiology|January 4, 2011
Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trialClaes Held, Nils Asenblad, Jean Pierre Bassand, et al.
European Heart Journal|March 25, 2014
Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trialJonathan P Piccini, Jyotsna Garg, Manesh R Patel, et al.
Circulation|December 6, 2012
Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohortsJonathan P Piccini, Susanna R Stevens, YuChiao Chang, et al.
European Heart Journal|October 18, 2013
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trialKenneth W Mahaffey, Susanna R Stevens, Harvey D White, et al.
Journal of the American Society of Nephrology : JASN|October 25, 2023
Effect of SGLT2 Inhibitors on Discontinuation of Renin-angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD TrialsRobert A Fletcher, Niels Jongs, Glenn M Chertow, et al.
Journal of the American Heart Association|June 22, 2023
Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE TrialsRobert A Fletcher, Clare Arnott, Patrick Rockenschaub, et al.
Pageof 64

Showing results (471-480 of 636) with videos related to

Sort By:
Pageof 64
The New England Journal of Medicine|November 6, 2012
Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis, Glenn M Chertow, Geoffrey A Block, et al.
Nature Medicine|June 24, 2024
Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trialJohannes F E Mann, Peter Rossing, George Bakris, et al.
International Journal of Cardiology|May 2, 2009
Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: results from SYNERGYSarah A Spinler, Kenneth W Mahaffey, Dianne Gallup, et al.
JAMA Cardiology|July 4, 2019
Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial FibrillationSean D Pokorney, DaJuanicia N Holmes, Laine Thomas, et al.
Journal of the American College of Cardiology|January 4, 2011
Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trialClaes Held, Nils Asenblad, Jean Pierre Bassand, et al.
European Heart Journal|March 25, 2014
Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trialJonathan P Piccini, Jyotsna Garg, Manesh R Patel, et al.
Circulation|December 6, 2012
Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohortsJonathan P Piccini, Susanna R Stevens, YuChiao Chang, et al.
European Heart Journal|October 18, 2013
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trialKenneth W Mahaffey, Susanna R Stevens, Harvey D White, et al.
Journal of the American Society of Nephrology : JASN|October 25, 2023
Effect of SGLT2 Inhibitors on Discontinuation of Renin-angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD TrialsRobert A Fletcher, Niels Jongs, Glenn M Chertow, et al.
Journal of the American Heart Association|June 22, 2023
Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE TrialsRobert A Fletcher, Clare Arnott, Patrick Rockenschaub, et al.
Pageof 64